ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2105

Stratification for elevated urate identifies a pro-inflammatory synovial fluid proteome in knee osteoarthritis: a pilot study

Tuhina Neogi1, Sayali Dhamne2, Robert Terkeltaub3, Virginia Kraus4, Simon Dillon5 and Towia Libermann5, 1Boston University School of Medicine, Boston, MA, 2Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 3Retired, San Diego, CA, 4Duke University, Durham, NC, 5Beth Israel Deaconess Medical Center, Boston, MA

Meeting: ACR Convergence 2025

Keywords: Inflammation, Osteoarthritis, proteomics, Uric Acid, Urate

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2079–2105) Osteoarthritis – Clinical Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: The causes of inflammation, pain fluctuations, and disease progression in osteoarthritis (OA) are not well understood. Soluble urate is a “danger signal”, and synovial fluid urate and IL-18, which along with IL-1β is a product of NLRP3 inflammasome activation, are associated with OA severity on imaging (PMID: 21245324) . In a pilot study, we evaluated differences in proteomic profiles of OA synovial fluid stratified by serum urate among people with OA but without gout to examine potential distinct OA phenotypes. We further explored whether the profiles differed by obesity or age as potential confounders in the association between urate and OA.

Methods: We obtained synovial fluid from individuals with knee OA but without a diagnosis of gout (and on no urate-lowering therapy) who had knee aspirations performed as part of standard clinical care (no crystals detected), and who consented to having their synovial fluid used for this pilot research study. The synovial fluid was immediately stored at 4oC, processed within 4 hours of collection, and then stored at -80oC. The samples were prepared with hyaluronidase and analyzed using the 11k SomaScan v5.0 proteomics assay that measures 10,778 proteins. Differentially expressed proteins were identified by t-tests and further evaluated using XLSTAT statistical software. Systems biology analysis used Ingenuity Pathway analysis (IPA) and STRING to define enriched pathophysiological pathways.

Results: We enrolled 30 participants (mean age 67 ± 11.6, 77% female, mean BMI 32.3 ± 6.9), of whom 47% (n=14) had serum urate >6 mg/dL (Elevated Urate Group (EUG). SomaScan analysis identified 186 proteins associated with the EUG that had an absolute fold change of at least 1.3 and p< 0.05. The top 30 proteins accurately discriminated between EUG and lower urate (Fig.1). IPA (Fig.2a) revealed enrichment of inflammatory response, particularly enhanced activity of the myeloid lineage and phagocytosis as key pathophysiological pathways in the EUG. Upstream regulator analysis confirmed that the predicted regulators with highest statistical significance involved enhanced activity of pro-inflammatory cytokines such as IL-1β and TNF and their downstream signaling mediators such as STAT3 and NFKB1. STRING analysis (Fig.2b) defined clusters of interacting proteins linked to inflammation, acute phase response, complement activation, and mRNA processing as key pathways. BMI-and age-associated protein signatures showed only limited overlap with the hyperuricemia-associated protein signature (Fig.3).

Conclusion: The synovial fluid proteome associated with higher urate in patients with OA included differential upregulation of pathways related to inflammation, phagocytosis, and the complement cascade compared with those whose serum urate was lower than 6.0 mg/dL. Furthermore, the protein signature associated with the EUG had minimal overlap with synovial fluid protein signatures associated with obesity or older age. Elevated urate, a biomarker of OA disease severity, may therefore contribute to an inflammatory profile in OA synovial fluid.

Supporting image 1Figure 1: Hierarchical Clustering of the Top 30 proteins* that had an absolute fold-change of ≥1.3 and p < 0.05 in differentiating the elevated urate group (>6mg/dL) from lower urate group

Supporting image 2Figure 2a: Upstream Regulators identified with Ingenuity Pathways Analysis (IPA) from among the top 30 proteins that had an absolute fold-change of ≥1.3 and p < 0.05 in differentiating the elevated urate group (>6mg/dL) from lower urate group based upon gene expression data. Proteins are listed in ascending order of statistical significance

Figure 2b: Clusters of Protein-Protein Interaction Networks identified with STRING Analysis from among the top 30 proteins that had an absolute fold-change of ≥1.3 and p < 0.05 in differentiating the elevated urate group (>6mg/dL) from lower urate group based upon protein expression data.

Supporting image 3Figure 3: Venn Diagram comparing differentially expressed proteins identified with p < 0.05 in the EUG vs. lower urate group, with differentially expressed proteins based upon obesity (BMI>30 vs. not) or Age (>65 vs. younger), demonstrating minimal overlap.


Disclosures: T. Neogi: None; S. Dhamne: None; R. Terkeltaub: Atom Bioscience, 2, BPG Bio, 2, Crystalys, 2, Novartis, 2, Shanton, 2; V. Kraus: 4-P Pharma, 1, Genascence, 1, Pacira, 1, Paradigm Biopharma, 1; S. Dillon: None; T. Libermann: None.

To cite this abstract in AMA style:

Neogi T, Dhamne S, Terkeltaub R, Kraus V, Dillon S, Libermann T. Stratification for elevated urate identifies a pro-inflammatory synovial fluid proteome in knee osteoarthritis: a pilot study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/stratification-for-elevated-urate-identifies-a-pro-inflammatory-synovial-fluid-proteome-in-knee-osteoarthritis-a-pilot-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/stratification-for-elevated-urate-identifies-a-pro-inflammatory-synovial-fluid-proteome-in-knee-osteoarthritis-a-pilot-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology